Circulating tumor DNA (ctDNA), circulating cancer cells (CTC), and biomarker evaluation of Nectin4, Trop2, and Her2neu in patients with muscle invasive bladder cancer (MIBC) receiving neoadjuvant chemotherapy (NAC) prior to robotic-assisted radical cystectomy.

Circulating tumor DNA (ctDNA), circulating cancer cells (CTC), and biomarker evaluation of Nectin4, Trop2, and Her2neu in patients with muscle invasive bladder cancer (MIBC) receiving neoadjuvant chemotherapy (NAC) prior to robotic-assisted radical cystectomy. - URO-TRACE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036191

Enrollment

Registered

2025-02-17

Start date

2025-05-15

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C67

Interventions

Group 1: Evaluation of the prognostic and predicitve value of ctDNA, CTC, and Nectin-4, Trop2, and Her2neu in patients with MIBC receiving NAC.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Capacity to consent

Exclusion criteria

Exclusion criteria: secondary malignancy

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the correlation of ctDNA, CTC and Nectin-4, Trop2 and Her2neu with overall survival and disease-free survival in patients with MIBC receiving NAC.	—

Secondary

Measure	Time frame
The secondary endpoints are to evaluate the predictive value of ctDNA, CTC and Nectin-4, Trop2 and Her2neu for treatment response to NAC, the diagnostic value of disease recurrence compared to CT follow-up and the predictive value of treatment response to antibody-drug conjugates.	—

Countries

Germany

Contacts

Public ContactPhilipp Nuhn

Klinik für Urologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel

jakob.kohler@uksh.de04315006537

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026